Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Oncogenic ras alleles are among the most common mutations found in patients with acute myeloid leukemia (AML). Previously, the role of oncogenic ras in cancer was assessed in model systems overexpressing oncogenic ras from heterologous promoters. However, there is increasing evidence that subtle differences in gene dosage and regulation of gene expression from endogenous promoters play critical roles in cancer pathogenesis. We characterized the role of oncogenic K-ras expressed from its endogenous promoter in the hematopoietic system using a conditional allele and IFN-inducible, Cre-mediated recombination. Mice developed a completely penetrant myeloproliferative syndrome characterized by leukocytosis with normal maturation of myeloid lineage cells; myeloid hyperplasia in bone marrow; and extramedullary hematopoiesis in the spleen and liver. Flow cytometry confirmed the myeloproliferative phenotype. Genotypic and Western blot analysis demonstrated Cre-mediated excision and expression, respectively, of the oncogenic K-ras allele. Bone marrow cells formed growth factor-independent colonies in methylcellulose cultures, but the myeloproliferative disease was not transplantable into secondary recipients. Thus, oncogenic K-ras induces a myeloproliferative disorder but not AML, indicating that additional mutations are required for AML development. This model system will be useful for assessing the contribution of cooperating mutations in AML and testing ras inhibitors in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617 · cited 3×
“Myeloid progenitors were distinguished as Lin–Sca-1–c-Kit+CD34+FcγRII/IIIlo common myeloid progenitors (CMPs), Lin–Sca-1–cKit+CD34+FcγRII/IIIhi granulocyte-monocyte progenitors (GMPs), and Lin–Sca-1–c-Kit+CD34–FcγII/IIIlo megakaryocyte-erythrocyte progenitors (MEPs) (43).”
BackgroundSelf-citationAnalysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898 · cited 4×
“floxed LSL–K-ras G12D allele (38) containing a transcriptional ter-”
BackgroundResultInfluentialSelf-citationDaley, G. Q., Van Etten, R. A., & Baltimore, D. (1990) · Science · doi:10.1126/science.2406902 · Cited by 1,756 · cited 4×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 537 Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, 52).”
InfluentialInducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641 · cited 4×
“In studies of Mx1-Cre–mediated recombination of a floxed DNA polymerase β gene, pI-pC treatment yielded high recombination efficiencies in hematopoietic tissues (liver, 100%; spleen, 94%; and thymus, 40%) and lower levels in nonhematopoietic tissues such as heart, kidney, lung, and duodenum (37).”
BackgroundMethodInfluentialThe roles of FLT3 in hematopoiesis and leukemia
Gilliland, D. G., & Griffin, J. D. (2002) · Blood · doi:10.1182/blood-2002-02-0492 · Cited by 1,558 · cited 1×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundSelf-citationSomatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 2×
“Papillomas and thymic lymphomas have been previously observed in 30% of adenovirus-Cre–treated oncogenic K-ras mice (40).”
BackgroundMethodSelf-citationSong, W.-J., Sullivan, M. G., Legare, R. D., Hutchings, S., Tan, X., Kufrin, D., Ratajczak, J., Resende, I. C., Haworth, C., Hock, R., et al. (1999) · Nature Genetics · doi:10.1038/13793 · Cited by 1,100 · cited 2×
“KM – 8–83 (35) 34–53 (41) 156–885 (583) 70–1,271 (540) 704–2,777 (1491) MPD n = 6 n = 6 n = 6 n = 8 n = 8”
BackgroundSelf-citationRodriguez-Viciana, P., Warne, P. H., Khwaja, A., Marte, B. M., Pappin, D., Das, P., Waterfield, M. D., Ridley, A., & Downward, J. (1997) · Cell · doi:10.1016/s0092-8674(00)80226-3 · Cited by 1,061
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792 · cited 1×
“Transgenic mice expressing viral H-ras from the MMTV promoter/enhancer developed B cell lymphoblastic lymphomas at low frequency (34).”
BackgroundUnderstanding Ras: ‘it ain’t over ’til it’s over’
Shields, J. M., Pruitt, K., McFall, A., Shaub, A., & Der, C. J. (2000) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01740-2 · Cited by 780
Tumour predisposition in mice heterozygous for a targeted mutation in Nf1
Jacks, T., Shih, T. S., Schmitt, E. M., Bronson, R. T., Bernards, A., & Weinberg, R. A. (1994) · Nature Genetics · doi:10.1038/ng0794-353 · Cited by 778 · cited 5×
“NF1-deficient mouse fetal liver cells demonstrate hypersensitivity to GM-CSF stimulation and elevated levels of ras-GTP (25, 26) and confer a JMML-like myeloproliferative disease upon transplantation (25).”
BackgroundInfluentialSelf-citationMultiple ras functions can contribute to mammalian cell transformation
White, M. A., Nicolette, C., Minden, A., Polverino, A., Aelst, L. V., Karin, M., & Wigler, M. H. (1995) · Cell · doi:10.1016/0092-8674(95)90507-3 · Cited by 649
p19ARF links the tumour suppressor p53 to Ras
Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 615
NF1 Tumor Suppressor Gene Function
Cichowski, K., & Jacks, T. (2001) · Cell · doi:10.1016/s0092-8674(01)00245-8 · Cited by 601 · cited 1×
“Loss-of-function mutations in neurofibromatosis 1 (NF1), a rasGAP protein, lead to accumulation of high levels of rasGTP (22).”
BackgroundSelf-citationBollag, G., Clapp, D. W., Shih, S., Adler, F., Zhang, Y. Y., Thompson, P., Lange, B. J., Freedman, M. H., McCormick, F., Jacks, T., et al. (1996) · Nature Genetics · doi:10.1038/ng0296-144 · Cited by 589 · cited 2×
“KM + 18–99 (36) 11–47 (26) 434–2,081 (1,194) 205–2,300 (677) 882–2,290 (1,703) MPD n = 22 n = 22 n = 22 n = 25 n = 25”
BackgroundSelf-citationTumor induction by an endogenous K-ras oncogene is highly dependent on cellular context
Guerra, C., Mijimolle, N., Dhawahir, A., Dubus, P., Barradas, M., Serrano, M., Campuzano, V., & Barbacid, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00191-0 · Cited by 571 · cited 2×
“In distinct contrast, primary mouse embryonic fibroblasts expressing endogenous levels of oncogenic K-ras bypass proliferative senescence and are immortalized (64).”
BackgroundK-ras is an essential gene in the mouse with partial functional overlap with N-ras
Johnson, L., Greenbaum, D., Cichowski, K., Mercer, K., Murphy, E., Schmitt, E., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 545 · cited 2×
“5 from severe anemia secondary to defects in the fetal liver microenvironment (39, 73).”
BackgroundMethodSelf-citationG ENETICS OF M YELOID L EUKEMIAS
Kelly, L. M., & Gilliland, D. G. (2002) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.3.032802.115046 · Cited by 523 · cited 1×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 529 requires a combination of mutations in the hematopoietic progenitor cells, which contribute to impaired differentiation and an increased proliferation and/or survival advantage (5, 6).”
BackgroundSelf-citationKelly, L. M., Liu, Q., Kutok, J. L., Williams, I. R., Boulton, C. L., & Gilliland, D. G. (2002) · Blood · doi:10.1182/blood.v99.1.310 · Cited by 487
Self-citationShannon, K. M., O'Connell, P., Martin, G. A., Paderanga, D., Olson, K., Dinndorf, P., & McCormick, F. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300903 · Cited by 444 · cited 5×
“NF1-deficient mouse fetal liver cells demonstrate hypersensitivity to GM-CSF stimulation and elevated levels of ras-GTP (25, 26) and confer a JMML-like myeloproliferative disease upon transplantation (25).”
BackgroundInfluentialHiguchi, M., O'Brien, D., Kumaravelu, P., Lenny, N., Yeoh, E.-J., & Downing, J. R. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00016-8 · Cited by 440 · cited 7×
“KM + 18–99 (36) 11–47 (26) 434–2,081 (1,194) 205–2,300 (677) 882–2,290 (1,703) MPD n = 22 n = 22 n = 22 n = 25 n = 25”
BackgroundInfluentialA PMLRAR α transgene initiates murine acute promyelocytic leukemia
Brown, D., Kogan, S., Lagasse, E., Weissman, I., Alcalay, M., Pelicci, P. G., Atwater, S., & Bishop, J. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2551 · Cited by 434
Distinct requirements for Ras oncogenesis in human versus mouse cells
Hamad, N. M., Elconin, J. H., Karnoub, A. E., Bai, W., Rich, J. N., Abraham, R. T., Der, C. J., & Counter, C. M. (2002) · Genes & Development · doi:10.1101/gad.993902 · Cited by 431
Myeloid or Lymphoid Promiscuity as a Critical Step in Hematopoietic Lineage Commitment
Miyamoto, T., Iwasaki, H., Reizis, B., Ye, M., Graf, T., Weissman, I. L., & Akashi, K. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00201-0 · Cited by 415 · cited 1×
“For analysis of myeloid progenitors, bone marrow cells were stained as previously described (42) and analyzed with a highly modified triple-laser FACS (488-nm argon laser, 599-nm dye laser, and UV laser; FACSVantage; Becton Dickinson Immunocytometry Systems, Mountain View, California, USA).”
MethodSelf-citationCritical role for Gab2 in transformation by BCR/ABL
Sattler, M., Mohi, M. G., Pride, Y. B., Quinnan, L. R., Malouf, N. A., Podar, K., Gesbert, F., Iwasaki, H., Li, S., Van Etten, R. A., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00074-0 · Cited by 364 · cited 1×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 537 Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, 52).”
BackgroundK-Ras is essential for the development of the mouse embryo
Koera, K., Nakamura, K., Nakao, K., Miyoshi, J., Toyoshima, K., Hatta, T., Otani, H., Aiba, A., & Katsuki, M. (1997) · Oncogene · doi:10.1038/sj.onc.1201284 · Cited by 355 · cited 1×
“5 from severe anemia secondary to defects in the fetal liver microenvironment (39, 73).”
BackgroundGrisolano, J. L., Wesselschmidt, R. L., Pelicci, P. G., & Ley, T. J. (1997) · Blood · doi:10.1182/blood.v89.2.376 · Cited by 352
Khosravi-Far, R., White, M. A., Westwick, J. K., Solski, P. A., Chrzanowska-Wodnicka, M., Van Aelst, L., Wigler, M. H., & Der, C. J. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3923 · Cited by 343
Acute leukemia with promyelocytic features in PML/RARα transgenic mice
He, L.-Z., Tribioli, C., Rivi, R., Peruzzi, D., Pelicci, P. G., Soares, V., Cattoretti, G., & Pandolfi, P. P. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5302 · Cited by 339
Stat5 Is Essential for the Myelo- and Lymphoproliferative Disease Induced by TEL/JAK2
Schwaller, J., Parganas, E., Wang, D., Cain, D., Aster, J. C., Williams, I. R., Lee, C.-K., Gerthner, R., Kitamura, T., Frantsve, J., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00067-8 · Cited by 303 · cited 1×
“The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4 537 Growth factor–independent colony-forming activity of bone marrow cells has also been described in TEL-JAK2 and BCR/ABL murine bone marrow transplant models (51, 52).”
BackgroundSelf-citationReuter, C. W. M., Morgan, M. A., & Bergmann, L. (2000) · Blood · doi:10.1182/blood.v96.5.1655 · Cited by 300 · cited 2×
“Oncogenic ras mutations are present in approximately 25–44% of AML patients and are among the most frequently detected genetic alterations in AML (12, 13).”
BackgroundThe pathogenesis of squamous cell cancer: lessons learned from studies of skin carcinogenesis
Yuspa, S. H. (1998) · Journal of Dermatological Science · doi:10.1016/s0923-1811(97)00071-6 · Cited by 300 · cited 1×
“Oncogenic ras mutations are detected in squamous papillomas and squamous cell carcinomas (57) and are important for initiation and progression of these lesions.”
BackgroundC-kit mutations in core binding factor leukemias
Beghini, A., Peterlongo, P., Ripamonti, C. B., Larizza, L., Cairoli, R., Morra, E., & Mecucci, C. (2000) · Blood · doi:10.1182/blood.v95.2.726 · Cited by 299 · cited 4×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundInfluentialLeder, A., Kuo, A., Cardiff, R. D., Sinn, E., & Leder, P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.23.9178 · Cited by 293 · cited 1×
“Transgenic mice expressing v-H-ras from the ζ-globin promoter develop skin papillomas with high frequency in response to trauma or chemical carcinogens (58).”
BackgroundOncogenic ras and p53 Cooperate To Induce Cellular Senescence
Ferbeyre, G., de Stanchina, E., Lin, A. W., Querido, E., McCurrach, M. E., Hannon, G. J., & Lowe, S. W. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.10.3497-3508.2002 · Cited by 290
Largaespada, D. A., Brannan, C. I., Jenkins, N. A., & Copeland, N. G. (1996) · Nature Genetics · doi:10.1038/ng0296-137 · Cited by 284 · cited 2×
“NF1-deficient mouse fetal liver cells demonstrate hypersensitivity to GM-CSF stimulation and elevated levels of ras-GTP (25, 26) and confer a JMML-like myeloproliferative disease upon transplantation (25).”
BackgroundResultFusion of ETV6 to Neurotrophin-3 Receptor TRKC in Acute Myeloid Leukemia With t(12;15)(p13;q25)
Eguchi, M., Eguchi-Ishimae, M., Tojo, A., Morishita, K., Suzuki, K., Sato, Y., Kudoh, S., Tanaka, K., Setoyama, M., Nagamura, F., et al. (1999) · Blood · doi:10.1182/blood.v93.4.1355 · Cited by 281
Sebti, S. M., & Hamilton, A. D. (2000) · Oncogene · doi:10.1038/sj.onc.1204146 · Cited by 279 · cited 1×
“Ultimately, these oncogenic K-ras/Mx1-Cre models will be useful for testing novel therapeutic agents, such as farnesyltransferase and geranylgeranyltransferase inhibitors, which target ras (65, 66), and other agents such as ERK inhibitors, which target the ras/MAP kinase pathway.”
BackgroundThe novel activation of ABL by fusion to an ets-related gene, TEL.
Papadopoulos, P., Ridge, S. A., Boucher, C. A., Stocking, C., & Wiedemann, L. M. (1995) · PubMed · Cited by 256
Schwaller, J., Frantsve, J., Aster, J., Williams, I. R., Tomasson, M. H., Ross, T. S., Peeters, P., Van Rompaey, L., Van Etten, R. A., Ilaria, R., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.18.5321 · Cited by 245 · cited 6×
“The overall hematopoietic phenotype was similar to the myeloproliferative diseases induced in murine bone marrow transplant assays by tyrosine kinase fusions such as BCR-ABL, TEL-PDGFRβ, TEL-TRKC, and TEL-JAK2 (17, 41, 45, 46).”
MethodInfluentialSelf-citationThe murine N-ras gene is not essential for growth and development.
Umanoff, H., Edelmann, W., Pellicer, A., & Kucherlapati, R. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1709 · Cited by 234 · cited 1×
“H-ras and N-ras knockout mice are viable with no overt abnormalities (71, 72).”
BackgroundDeguchi, K., Ayton, P. M., Carapeti, M., Kutok, J. L., Snyder, C. S., Williams, I. R., Cross, N. C. P., Glass, C. K., Cleary, M. L., & Gilliland, D. G. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00051-5 · Cited by 225 · cited 1×
“Serial replating assays were performed as previously described (44) in two independent experiments with 104 cells replated in duplicate for each round of replating and colony counts performed on day 7.”
MethodSelf-citationRAS and Leukemia: From Basic Mechanisms to Gene-Directed Therapy
Beaupre, D. M., & Kurzrock, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.1071 · Cited by 192 · cited 6×
“Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25).”
BackgroundInfluentialEllis, C. A., & Clark, G. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00084-x · Cited by 192 · cited 2×
“In addition, ras isoforms differ with respect to post-translational modifications, subcellular localization, and transformation properties (7, 11).”
BackgroundNeshat, M. S., Raitano, A. B., Wang, H.-G., Reed, J. C., & Sawyers, C. L. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1179-1186.2000 · Cited by 185
Nishizaki, T., DeVries, S., Chew, K., Goodson, W. H., Ljung, B., Thor, A. D., & Waldman, F. M. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199708)19:4<250::aid-gcc7>3.0.co;2-w · Cited by 184
Gilliland, D. G. (2001) · Current Opinion in Hematology · doi:10.1097/00062752-200107000-00001 · Cited by 161
Self-citationTargeted deletion of the H-ras gene decreases tumor formation in mouse skin carcinogenesis
伊勢, 和., Nakamura, K., Nakao, K., Shimizu, S., Harada, H., Ichise, T., Miyoshi, J., Gondo, Y., Ishikawa, T., Aiba, A., et al. (2000) · Oncogene · doi:10.1038/sj.onc.1203600 · Cited by 132 · cited 1×
“H-ras and N-ras knockout mice are viable with no overt abnormalities (71, 72).”
BackgroundTomasson, M. H., Sternberg, D., Williams, I. R., Carroll, M. P., Cain, D., Aster, J. C., Ilaria, R. L., Etten, R. A. V., & Gilliland, D. G. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8902 · Cited by 111
Self-citationLiu, Q., Schwaller, J., Kutok, J. L., Cain, D., Aster, J. C., Williams, I. R., & Gilliland, D. G. (2000) · The EMBO Journal · doi:10.1093/emboj/19.8.1827 · Cited by 110 · cited 7×
“The overall hematopoietic phenotype was similar to the myeloproliferative diseases induced in murine bone marrow transplant assays by tyrosine kinase fusions such as BCR-ABL, TEL-PDGFRβ, TEL-TRKC, and TEL-JAK2 (17, 41, 45, 46).”
BackgroundInfluentialSelf-citationHaplo-insufficiency? Let me count the ways: Figure 1.Preprint
Quon, K. C., & Berns, A. J. M. (2001) · Genes & Development · doi:10.1101/gad.949001 · Cited by 109 · cited 2×
“KM + 18–99 (36) 11–47 (26) 434–2,081 (1,194) 205–2,300 (677) 882–2,290 (1,703) MPD n = 22 n = 22 n = 22 n = 25 n = 25”
BackgroundRas redux: rethinking how and where Ras acts
Hingorani, S. R., & Tuveson, D. A. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00017-5 · Cited by 103 · cited 3×
“More recently, it has been hypothesized that thresholds of ras activity exist, such that low, intermittent signaling contributes to cellular homeostasis; modest increases promote proliferation without triggering protective tumor suppressor or growth arrest pathways; and high, sustained levels induce growth arrest and…”
BackgroundSelf-citationMutant N-ras Induces Myeloproliferative Disorders and Apoptosis in Bone Marrow Repopulated Mice
MacKenzie, K. L., Dolnikov, A., Millington, M., Shounan, Y., & Symonds, G. P. (1999) · Blood · doi:10.1182/blood.v93.6.2043.406k17_2043_2056 · Cited by 99 · cited 3×
“In a transplant model using bone marrow cells retrovirally transduced with oncogenic N-ras, recipient mice developed myeloproliferative disorders with long latency (107–385 days) and incomplete penetrance, suggesting that secondary mutations were necessary for the phenotype (30).”
BackgroundResultBar-Sagi, D. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1441-1443.2001 · Cited by 85
Nguyen, M. H.-H., Ho, J., Beattie, B. K., & Barber, D. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103100200 · Cited by 68 · cited 1×
“3) 43–50 (47) 551–1,336 (1,074) 67–120 (90) 1,069–1,756 (1,437) Normal n = 9 n = 9 n = 9 n = 10 n = 10”
Mutant N-RAS Induces Erythroid Lineage Dysplasia in Human CD34+ Cells
Darley, R. L., Hoy, T. G., Baines, P., Padua, R. A., & Burnett, A. K. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.7.1337 · Cited by 68 · cited 1×
“CD34+ stem cells transduced with amphotrophic retrovirus expressing oncogenic N-ras had impaired erythropoietin-induced erythroid differentiation at the late erythroblast stage, reminiscent of a myelodysplastic phenotype (27, 28), and impaired G-CSF– and GM-CSF– induced granulocytic differentiation at the blast/promye…”
BackgroundLiver metastasis formation by laminin-1 peptide (LQVQLSIR)-adhesion selected B16-F10 melanoma cells
Song, S.-Y., Nomizu, M., Yamada, Y., & Kleinman, H. K. (1997) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19970502)71:3<364::aid-ijc10>3.0.co;2-g · Cited by 57 · cited 1×
“In rare instances, activating ras mutations have been reported in lymphomas (59).”
BackgroundMillion, R. P., Aster, J. C., Gilliland, D. G., & Etten, R. A. V. (2002) · Blood · doi:10.1182/blood-2001-12-0244 · Cited by 55 · cited 3×
“Most of these tyrosine kinase mutations confer growth factor–independent growth to hematopoietic cell lines and cause a myeloproliferative disease in mouse models (17, 20, 21).”
BackgroundSelf-citationSternberg, D., Tomasson, M. H., Carroll, M. P., Curley, D. P., Barker, G., Caprio, M., Wilbanks, A. M., Kazlauskas, A., & Gilliland, D. G. (2001) · Blood · doi:10.1182/blood.v98.12.3390 · Cited by 53
Self-citationHematopoietic transforming potential of activated ras in chimeric mice.
Hawley, R. G., Fong, A. Z. C., Ngan, B., & Hawley, T. S. (1995) · PubMed · Cited by 48
Schneider, A., Zhang, Y., Guan, Y., Davis, L. S., & Breyer, M. D. (2003) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00235.2002 · Cited by 43 · cited 1×
“Experiments with mice doubly transgenic for the β-galactosidase reporter ROSA26tm1Sor and Mx1-Cre demonstrate Cre expression in liver, spleen, pulmonary endothelium, kidney, and gastric epithelium (60).”
BackgroundInvolvement of the TEL Gene in Hematologic Malignancy by Diverse Molecular Genetic Mechanisms
Golub, T. R., Barker, G. F., Stegmaier, K., & Gilliland, D. G. (1996) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-85232-9_28 · Cited by 38 · cited 1×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundSelf-citationDierov, J. K., Xu, Q., Dierova, R., & Carroll, M. P. (2002) · Blood · doi:10.1182/blood.v99.5.1758 · Cited by 33
Mangues, R., Symmans, W. F., Lu, S., Schwartz, S., & Pellicer, À. (1996) · PubMed · Cited by 33
Scheele, J. S., Räpple, D., & Lübbert, M. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000675 · Cited by 31 · cited 2×
“Examples of tyrosine kinase gain-of-function mutations in AML include FLT3 activation loop point mutations, FLT3 juxtamembrane region internal tandem duplications (ITDs) (14), C-KIT point mutations (15), and the tyrosine kinase fusion products of chromosomal translocations such as TEL/ TRKC associated with t(12;15) (1…”
BackgroundAhmadian, M. R. (2002) · British Journal of Haematology · doi:10.1046/j.0007-1048.2001.03314.x · Cited by 30 · cited 1×
“Ultimately, these oncogenic K-ras/Mx1-Cre models will be useful for testing novel therapeutic agents, such as farnesyltransferase and geranylgeranyltransferase inhibitors, which target ras (65, 66), and other agents such as ERK inhibitors, which target the ras/MAP kinase pathway.”
BackgroundDarley, R. L., Pearn, L., Omidvar, N., Sweeney, M., Fisher, J., Phillips, S., Hoy, T., & Burnett, A. K. (2002) · Blood · doi:10.1182/blood-2002-05-1358 · Cited by 27 · cited 1×
“CD34+ stem cells transduced with amphotrophic retrovirus expressing oncogenic N-ras had impaired erythropoietin-induced erythroid differentiation at the late erythroblast stage, reminiscent of a myelodysplastic phenotype (27, 28), and impaired G-CSF– and GM-CSF– induced granulocytic differentiation at the blast/promye…”
BackgroundMolecular mechanisms of tumor progression in chronic myeloproliferative disorders.
Gaïdano, G., Guerrasio, A., Serra, A., Rege‐Cambrin, G., & Saglio, G. N. (1994) · PubMed · Cited by 24
Dunbar, C. E., Crosier, P., & Nienhuis, A. W. (1991) · PubMed · Cited by 22
N‐ras and p53 gene mutations in Japanese patients with myeloproliferative disorders
Tsurumi, S., Nakamura, Y., Maki, K., Omine, M., Fujita, K., Okamura, T., Niho, Y., Hashimoto, S., Kanno, K., Suzuki, K., et al. (2002) · American Journal of Hematology · doi:10.1002/ajh.10188 · Cited by 18
Mavrogianni, D., Viniou, N. A., Michali, E., Terpos, E., Meletis, J., Vaiopoulos, G., Madzourani, M., Pangalis, G. A., Yataganas, X., & Loukopoulos, D. (2002) · International Journal of Hematology · doi:10.1007/bf02982131 · Cited by 15
Mutant N-RAS blocks granulocytic differentiation of human cd34+ cells
Darley, R. L., Hoy, T. G., Robinson, L., & Burnett, A. K. (1998) · ORCA Online Research @Cardiff (Cardiff University) · doi:10.1111/j.1365-2141.1998.tb08997.x · Cited by 1
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
“DH p185 (1-426) p210 (1-902–927) p230 (1–1,176) Y177 Myr GAG BCR F G 1a 1b”
Krebs, A. M., Mitschke, J., Lasierra Losada, M., Schmalhofer, O., Boerries, M., Busch, H., Boettcher, M., Mougiakakos, D., Reichardt, W., Bronsert, P., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3513 · Cited by 975
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Self-citation
Metadata
- Authors
- Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Kelly, L., Shigematsu, H., Johnson, L., Akashi, K., Tuveson, D. A., Jacks, T., & Gilliland, D. G.
- Affiliations
- Brigham and Women's Hospital (US)
- Emory University (US)
- Harvard University (US)
- Dana-Farber Cancer Institute (US)
- Exelixis (United States) (US)
- Abramson Cancer Center (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Gilliland, D. Gary
- Venue
- Journal of Clinical Investigation
- Published
- 2004-02-15
- Volume
- 113
- Issue
- 4
- Pages
- 528-538
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC338267
- OpenAlex
- W2147839086
- Cited by
- 270
- References
- 73
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 9 · 2020: 3 · 2019: 8 · 2018: 8 · 2017: 12 · 2016: 9 · 2015: 10 · 2014: 13 · 2013: 16 · 2012: 12
- FWCI
- 14.27
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Howard Hughes Medical Institute
- Leukemia and Lymphoma Society
- National Institutes of Health (CA66996)
- National Cancer Institute (#CA66996, P01CA066996)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK51564)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Keywords
- oncogenic KRAS, endogenous promoter, conditional alleles, Cre-mediated recombination, myeloproliferative neoplasms, acute myeloid leukemia, hematopoietic system, myeloid hyperplasia, extramedullary hematopoiesis, cooperating mutations, RAS inhibitors, gene dosage
- MeSH terms
- Adenoma, Alleles, Animals, Bone Marrow Cells, Cells, Cultured, Hematopoietic Stem Cells, Humans, Mice, Inbred Strains, Mice, Transgenic, Myeloproliferative Disorders, Neoplasms, Papilloma, Phenotype, Promoter Regions, Genetic, Genes, ras, Leukemia, Myeloid, Acute, Gene Expression Regulation, Neoplastic, Bone Marrow Transplantation, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.